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Abstract 
Despite promising clinical trials, intravenous immunoglobulin (IVIg) therapy in 
relapsing-remitting multiple sclerosis has met with uncertainties that might be 
attributed to small patient cohorts, heterogeneity in the patients, dosage of IVIg, and 
the duration and window of treatment.  
 
Key words: IVIg, multiple sclerosis, biomarkers, immunotherapy, autoimmunity, 
inflammation 
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Multiple sclerosis (MS) is the most common chronic inflammatory disease of the 
central nervous system (CNS). Aberrant immune responses in patients lead to 
demyelination and axonal degeneration, causing accumulated disability and reduced 
life expectancy[1]. The disease is highly heterogeneous, and the majority of patients 
are initially diagnosed with relapsing-remitting multiple sclerosis (RRMS). RRMS is 
characterized by worsening of neurological symptoms followed by remission that 
may be complete initially but only partial as the disease advances. Although new 
drugs such as natalizumab, fingolimod, teriflunomide, dimethylfumarate and 
alemtuzumab have been recently added to the traditional therapeutic armamentarium 
of interferon β, glatiramer acetetate and mitoxantrone, safety issues continue, 
particularly during pregnancy and lactation periods and long-term use, which keeps 
clinicians looking for alternative therapies. 
The basis for IVIg therapy in RRMS 
Intravenous immunoglobulin (IVIg), a pooled preparation of normal IgG obtained 
from the plasma of several thousand healthy donors was initially used for the 
replacement therapy of primary and secondary immunodeficiencies. Seminal work on 
therapeutic utility of IVIg in the treatment of immune thrombocytopenia by Imbach in 
1981 encouraged exploration of IVIg therapy in a number of conditions considered to 
be autoimmune in nature. Subsequently, IVIg has been established as first-line 
therapy for many autoimmune and inflammatory conditions including Guillain-Barré 
syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.  
Based on observations in basic research, animal models and patient studies, it was 
proposed that IVIg provides benefit to patients with autoimmune disorders via several 
mutually nonexclusive mechanisms: inhibition of activation of macrophages, 
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dendritic cells and pathogenic T cells such as Th1 and Th17 cells; expansion of 
regulatory T cells; modulation of B cell responses and inhibition of pathogenic 
autoantibody production; suppression of production of inflammatory cytokines and 
stimulation of anti-inflammatory cytokines; neutralization of pathogenic 
autoantibodies via anti-idiotypes and inhibition of activation of endothelial cells and 
complement[2]. These data, a proven track record of minimal side effects in treated 
patients and promising results obtained with experimental models of MS and several 
case reports prompted the initiation of clinical trials for exploring utility of IVIg 
therapy in RRMS (Figure 1). 
Initial positive clinical trials 
The initial four clinical studies from Europe showed beneficial effects of IVIg for 
RRMS. In the Austrian study, patients received monthly doses of 0.15 to 0.2 g/kg for 
the period of 2 years[3]. This randomized, double-blind, placebo-controlled, multi-
centre study reported that monthly IVIg infusion is beneficial to reduce the evolution 
of further clinical disability as measured by the absolute change in Kurtzke's 
expanded disability status scale score (EDSS).  
In 1998 two studies reported benefits of IVIg for RRMS[4, 5]. The study from Israel 
was randomized, double-blind and placebo-controlled [4].  The dose of IVIg was 
0.4g/kg over five days and followed by 0.4g/kg for every two months for two years. 
IVIg-treated patients showed significant reduction in yearly exacerbation rate while 
six patients were completely relapse-free. Also, the median time to first exacerbation 
was three times higher in the IVIg group. Although analysis of total lesions by brain 
magnetic resonance imaging (MRI) did not reveal significant differences between two 
groups, this study suggested that IVIg is effective in reducing relapse rate in RRMS.  
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The Danish study was a randomized, double-blind, crossover study [5]. One group 
was treated with IVIg on a monthly basis for six months at 1g/kg given on two 
consecutive days. After three months of washout period, patients received placebo for 
6 months. The second group was treated in reverse order. The number of 
exacerbation-free patients was significantly higher during IVIg treatment. Also, serial 
MRI revealed significantly fewer enhancing lesions per patient/scan during IVIg 
treatment. A double-blind, placebo-controlled study in Poland reported that IVIg dose 
0.2 g/kg administered once a month for 12 months is equally effective as 0.4 g/kg in 
reducing MS activity[6]. Subsequent data from a retrospective multicenter 
observational study over five years reported that IVIg treatment 
(0.24±0.15g/kg/month) resulted in 69% reduction in mean annual relapse rate[7]. 
Collectively, these studies suggested that IVIg is effective in reducing relapse rate in 
RRMS. 
Due to safety issues of currently licensed MS drugs during pregnancy and lactation 
periods, as a retrospective study, IVIg was explored in pregnant patients with 
RRMS[8]. Patients received IVIg for the whole pregnancy (0.4 g/kg/day for 5 
consecutive days within first 6-8 weeks of pregnancy followed by 0.4 g/kg/day every 
6 weeks until 12 weeks post-partum) had significantly diminished relapse 
rate/woman/year as compared to untreated patients.  Another multinational, multi-
centre, randomized double-blind clinical trial also supported usefulness of IVIg in 
postpartum RRMS[9].  
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The negative data 
The excitement emanating from these successful trials receded when a subsequent 
multi-center, randomized, double-blind, placebo-controlled trial PRIVIG reported 
ineffectiveness of IVIg for RRMS[10]. This study involving two doses of IVIg (0.2 
and 0.4 g/kg every 4 weeks for 12 months) demonstrated that the proportion of 
relapse-free patients and cumulative number of unique newly active MRI lesions did 
not differ among IVIg-treated groups and placebo.  
Reasons for uncertainties  
While many auto-inflammatory diseases have proven responsive to IVIg therapy, the 
outcome of these MS trials remains somewhat of a conundrum. Several factors might 
have contributed to the equivocal observations. Foremost, the heterogeneous nature of 
the disease and its underlying pathobiology may be confounding factors. In all these 
clinical trials, patients groups were not uniform and cohorts were relatively small 
(Figure 1).  
Another important reason for uncertainties with these trials is the dosage, window and 
duration of the IVIg treatment employed. At least four different dose regimens were 
used in the above studies. Currently, high-dose IVIg therapy, typically 1-2g/kg 
infused as either single dose or over two or five consecutive days, is commonly used 
to treat autoimmune and inflammatory diseases. Two of the clinical trials and a 
retrospective study in pregnant patients with RRMS that reported beneficial effects of 
IVIg had adopted this dose regimen. However, in other studies including the PRIVIG 
study [10], the dose of IVIg administered to the patients correspond to replacement 
doses used in primary and secondary immunodeficiencies (0.4 g/kg every four weeks) 
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or were even lower. Thus, cumulative dose of IVIg used in the PRIVIG study might 
have been too low to be efficacious (Figure 1). 
The next steps 
One way to deal with the challenge of disease heterogeneity would be the 
identification of biomarkers associated with therapeutic responsiveness to IVIg in an 
individual patient. Functional genomics has been recently performed to predict IVIg 
response in RRMS patients[11]. This GAM-25 study indicates that a combination of 
genotyping and 65 functional immune parameters such as modulation of Fc-receptors, 
cytokines, chemokines and natural killer cells subjected to a stepwise linear 
discriminant analysis, could be used to distinguish patients who benefit from IVIg 
therapy from those who do not. Applying a scoring system based on these parameters, 
it was suggested that RRMS patients with mild disease respond to IVIg therapy. The 
cohort enrolled in this study was small, without control group and hence data were 
only suggestive. However, this study should form a platform for a validation trial 
involving more patients. Importantly, a prospective, multi-centre, active-controlled, 
randomized Phase IIIb trial is underway with a larger number of patients by the same 
authors (http://www.isrctn.com/ISRCTN82177408). As the GAM-25 study utilized an 
IVIg dose that corresponds to replacement therapy (0.4 g/kg for every four weeks 
until study termination), clinical trials should be considered with high-dose IVIg (1-2 
g/kg) therapy as well. The molecular and immunological biomarkers that were used in 
other autoimmune patients to segregate IVIg responders could also be tested in future 
trials[12]. If subtype, activity and response marker studies yield conclusive results that 
predict which patients will profit from IVIg, a safe new addition to the therapeutic 
armamentarium to battle this crippling disease would be available. It is hoped that 
	   8	  
IVIg then could be optimized and streamlined with precise anti-inflammatory dosage, 
optimal window of treatment and duration of therapy. 
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Figure legend 
Figure 1. The promises and uncertainties of IVIg therapy for relapsing-remitting 
multiple sclerosis (RRMS). The rationales for the IVIg therapy in RRMS are 
presented on the left side (‘happy face’), while the possible reasons for uncertainties 
with IVIg therapy are depicted on the right side (‘sad face’).   
 
 
 
 
